1. Home
  2. EVO vs VRDN Comparison

EVO vs VRDN Comparison

Compare EVO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVO
  • VRDN
  • Stock Information
  • Founded
  • EVO 1993
  • VRDN 2006
  • Country
  • EVO Germany
  • VRDN United States
  • Employees
  • EVO N/A
  • VRDN N/A
  • Industry
  • EVO Biotechnology: Pharmaceutical Preparations
  • VRDN Medical Specialities
  • Sector
  • EVO Health Care
  • VRDN Health Care
  • Exchange
  • EVO Nasdaq
  • VRDN Nasdaq
  • Market Cap
  • EVO 1.6B
  • VRDN 1.6B
  • IPO Year
  • EVO 2021
  • VRDN N/A
  • Fundamental
  • Price
  • EVO $3.60
  • VRDN $13.13
  • Analyst Decision
  • EVO Buy
  • VRDN Buy
  • Analyst Count
  • EVO 2
  • VRDN 12
  • Target Price
  • EVO $5.90
  • VRDN $36.44
  • AVG Volume (30 Days)
  • EVO 101.3K
  • VRDN 1.2M
  • Earning Date
  • EVO 04-17-2025
  • VRDN 05-07-2025
  • Dividend Yield
  • EVO N/A
  • VRDN N/A
  • EPS Growth
  • EVO N/A
  • VRDN N/A
  • EPS
  • EVO N/A
  • VRDN N/A
  • Revenue
  • EVO $825,103,013.00
  • VRDN $302,000.00
  • Revenue This Year
  • EVO $3.70
  • VRDN N/A
  • Revenue Next Year
  • EVO $10.32
  • VRDN $20,553.29
  • P/E Ratio
  • EVO N/A
  • VRDN N/A
  • Revenue Growth
  • EVO 1.99
  • VRDN N/A
  • 52 Week Low
  • EVO $2.84
  • VRDN $9.90
  • 52 Week High
  • EVO $7.77
  • VRDN $27.20
  • Technical
  • Relative Strength Index (RSI)
  • EVO 56.15
  • VRDN 46.75
  • Support Level
  • EVO $3.27
  • VRDN $9.90
  • Resistance Level
  • EVO $3.40
  • VRDN $14.22
  • Average True Range (ATR)
  • EVO 0.14
  • VRDN 1.17
  • MACD
  • EVO 0.07
  • VRDN 0.18
  • Stochastic Oscillator
  • EVO 84.44
  • VRDN 74.77

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Share on Social Networks: